Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670330 · ClinicalTrials.gov registry record · Phase 3
Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
A Phase 3 study, sponsored by Scioderm.
- Terminated
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
NCT02670330 is a Phase 3 study that was terminated before completion, run by Scioderm. The registered enrollment target is 152 participants.
The verdict
NCT02670330, a Phase 3 study, was terminated before completion, sponsored by Scioderm.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
Study Summary
The study aimed to assess the long-term safety of topical use of Zorblisa (SD-101-6.0) in participants with Epidermolysis Bullosa (EB).
Interventions
- DRUG SD-101-6.0 cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2015-06-09 |
| Est. Completion | 2018-09-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02670330
The ClinicalTrials.gov registry entry for NCT02670330 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scioderm, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SD-101-6.0 cream is the first listed.
NCT02670330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02670330 about?
NCT02670330 is a clinical study titled "Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa". The study aimed to assess the long-term safety of topical use of Zorblisa (SD-101-6.0) in participants with Epidermolysis Bullosa (EB).
What is the current status of trial NCT02670330?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2015-06-09. Estimated completion is 2018-09-03.
What interventions are being tested in trial NCT02670330?
The interventions under investigation include: SD-101-6.0 cream (DRUG).
Who is sponsoring clinical trial NCT02670330?
This trial is sponsored by Scioderm, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.